Skip to content

Study · In vitro (cells) · mouse · 2014

4 results

Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia.

Joshi D, Abraham D, Shiwen X, Baker D, Tsui J

Journal of vascular surgery20 Sept 2013Cited by 20 (Europe PMC)

PMID24055514 (opens in a new tab)DOI10.1016/j.jvs.2013.06.054 (opens in a new tab)PepBankPUB-24055514
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In ischemic C2C12 myotubes, ARA‑290 reduced the share of apoptotic cells from 71.1% to 55.1%.

    In plain wordsIn mouse muscle cells under simulated ischemia, ARA‑290 reduced the share of dying cells.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseApoptotic cells in ischemic myotubes
    Study

    mousen: not reported in source

    C2C12 myotubes under simulated ischemia
    Comparator
    Simulated ischemia without ARA 290
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Apoptotic cells
    71.1%
    ischemia
    Apoptotic cells
    55.1%
    ischemia plus ARA 290

    Source sentences

    Summary
    had a significantly decreased number of apoptotic cells (ischemia vs ischemia plus ARA 290: 71.1% vs 55.1%; P < .01
    1 context sentence
    Summary · context
    A validated in vitro model of myotube ischemia was used in which mature C2C12 myotubes were cultured 6 to 12 hours in a depleted media and gas mixture (20% CO2 and 80% N2). The myotubes were pretreated with EPO or ARA 290 before exposure to simulated ischemia.
  2. 02LabIn vitro (cells)Activity measurement

    In ischemic C2C12 myotubes, ARA‑290 lowered cleaved caspase-3 (optical density 0.15 to 0.02 U).

    In plain wordsIn mouse muscle cells under simulated ischemia, ARA‑290 lowered a marker of cell death.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseCleaved caspase-3 in ischemic myotubes
    Study

    mousen: not reported in source

    C2C12 myotubes under simulated ischemia
    Comparator
    Simulated ischemia without ARA 290
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Cleaved caspase-3 OD
    0.15 U
    ischemia
    Cleaved caspase-3 OD
    0.02 U
    ischemia plus ARA 290

    Source sentences

    Summary
    cleaved caspase-3 (OD of ischemia vs ischemia plus ARA 290: 0.15 U vs 0.02 U; P < .01
    1 context sentence
    Summary · context
    A validated in vitro model of myotube ischemia was used in which mature C2C12 myotubes were cultured 6 to 12 hours in a depleted media and gas mixture (20% CO2 and 80% N2). The myotubes were pretreated with EPO or ARA 290 before exposure to simulated ischemia.
  3. 03LabIn vitro (cells)Activity measurement

    In ischemic C2C12 myotubes, ARA‑290 reduced lactate dehydrogenase release from 32.5 to 21.3 U/L.

    In plain wordsIn mouse muscle cells under simulated ischemia, ARA‑290 reduced release of an enzyme that shows cell damage.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseLactate dehydrogenase release from ischemic myotubes
    Study

    mousen: not reported in source

    C2C12 myotubes under simulated ischemia
    Comparator
    Simulated ischemia without ARA 290
    Outcome group
    Muscle injury and repair · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    LDH release
    32.5 U/L
    ischemia
    LDH release
    21.3 U/L
    ischemia plus ARA 290

    Source sentences

    Summary
    lactate dehydrogenase release (ischemia vs ischemia plus ARA 290: 32.5 U/L vs 21.3 U/L; P < .01
    1 context sentence
    Summary · context
    A validated in vitro model of myotube ischemia was used in which mature C2C12 myotubes were cultured 6 to 12 hours in a depleted media and gas mixture (20% CO2 and 80% N2). The myotubes were pretreated with EPO or ARA 290 before exposure to simulated ischemia.
  4. 04LabIn vitro (cells)Activity measurement

    In ischemic C2C12 myotubes, ARA‑290 reduced interleukin-6 release (optical density 0.18 to 0.13).

    In plain wordsIn mouse muscle cells under simulated ischemia, ARA‑290 reduced release of the inflammatory signal IL-6.

    Peptide
    Cibinetide (ARA-290)
    Outcome
    DecreaseIL-6 release from ischemic myotubes
    Study

    mousen: not reported in source

    C2C12 myotubes under simulated ischemia
    Comparator
    Simulated ischemia without ARA 290
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated

    Measurements

    IL-6 release OD at 450 nm
    0.18
    ischemia
    IL-6 release OD at 450 nm
    0.13
    ischemia plus ARA 290

    Source sentences

    Summary
    IL-6 release (OD at 450 nm, ischemia vs ischemia plus ARA 290: 0.18 vs 0.13; P < .01
    1 context sentence
    Summary · context
    A validated in vitro model of myotube ischemia was used in which mature C2C12 myotubes were cultured 6 to 12 hours in a depleted media and gas mixture (20% CO2 and 80% N2). The myotubes were pretreated with EPO or ARA 290 before exposure to simulated ischemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.